OXU 005
Alternative Names: OXU-005Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Oxular
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Age-related macular degeneration
- No development reported Diabetic retinopathy
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Diabetic-retinopathy in United Kingdom (Ophthalmic, Controlled release)
- 20 Jul 2022 Oxular plans phase II trial for Diabetic retinopathy in 2025 (Oxular pipeline, August 2022)
- 20 Jul 2022 Oxular plans to submit IND application for Diabetic retinopathy in 2024 (Oxular pipeline, July 2022)